Literature DB >> 34590285

Computational Prediction of Chemical Tools for Identification and Validation of Synthetic Lethal Interaction Networks.

Kalpana K Bhanumathy1, Omar Abuhussein2, Frederick S Vizeacoumar3,4, Andrew Freywald4, Franco J Vizeacoumar1,5, Christopher P Phenix6, Eric W Price6, Ran Cao7.   

Abstract

Cancer is one of the leading causes of death and chromosomal instability (CIN) is a hallmark feature of cancer. CIN, a source of genetic variation in either altered chromosome number or structure contributes to tumor heterogeneity and has become a hot topic in recent years prominently for its role in therapeutic responses. Synthetic lethality and synthetic rescue based approaches, for example, advancing CRISPR-Cas9 platform, are emerging as a powerful strategy to identify new potential targets to selectively eradicate cancer cells. Unfortunately, only few of them are further explored therapeutically due to the difficulty in linking these targets to small molecules for pharmacological intervention. This, however, can be alleviated by the efforts to bring chemical, bioactivity, and genomic data together, as well as established computational approaches. In this chapter, we will discuss some of these advances, including established databases and in silico target-ligand prediction, with the aim to navigate through the synthetically available chemical space to the biologically targetable landscape, and eventually, to the chemical modeling of synthetic lethality and synthetic rescue interactions, that are of great clinical and pharmaceutical relevance and significance.
© 2021. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Bioactivity database; Chemical library; De novo design; Synthetic lethality; Virtual screening

Mesh:

Substances:

Year:  2021        PMID: 34590285     DOI: 10.1007/978-1-0716-1740-3_18

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  118 in total

1.  Marc Kirschner. Interview by Asher Mullard.

Authors:  Marc Kirschner
Journal:  Nat Rev Drug Discov       Date:  2011-12-01       Impact factor: 84.694

Review 2.  Docking and scoring in virtual screening for drug discovery: methods and applications.

Authors:  Douglas B Kitchen; Hélène Decornez; John R Furr; Jürgen Bajorath
Journal:  Nat Rev Drug Discov       Date:  2004-11       Impact factor: 84.694

Review 3.  Opportunities for structure-based design of protease-directed drugs.

Authors:  Peer Re Mittl; Markus G Grütter
Journal:  Curr Opin Struct Biol       Date:  2006-11-16       Impact factor: 6.809

Review 4.  FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.

Authors:  Geoffrey Kim; Gwynn Ison; Amy E McKee; Hui Zhang; Shenghui Tang; Thomas Gwise; Rajeshwari Sridhara; Eunice Lee; Abraham Tzou; Reena Philip; Haw-Jyh Chiu; Tiffany K Ricks; Todd Palmby; Anne Marie Russell; Gaetan Ladouceur; Elimika Pfuma; Hongshan Li; Liang Zhao; Qi Liu; Rajesh Venugopal; Amna Ibrahim; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2015-07-17       Impact factor: 12.531

Review 5.  Structure-based drug screening for G-protein-coupled receptors.

Authors:  Brian K Shoichet; Brian K Kobilka
Journal:  Trends Pharmacol Sci       Date:  2012-04-13       Impact factor: 14.819

Review 6.  A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality.

Authors:  Sreejit Parameswaran; Deeksha Kundapur; Frederick S Vizeacoumar; Andrew Freywald; Maruti Uppalapati; Franco J Vizeacoumar
Journal:  Trends Cancer       Date:  2018-12-07

Review 7.  Building high-resolution synthetic lethal networks: a 'Google map' of the cancer cell.

Authors:  James M Paul; Shaina D Templeton; Akanksha Baharani; Andrew Freywald; Franco J Vizeacoumar
Journal:  Trends Mol Med       Date:  2014-10-22       Impact factor: 11.951

8.  Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.

Authors:  Jun Feng; Zhiyuan Zhang; Michael B Wallace; Jeffrey A Stafford; Stephen W Kaldor; Daniel B Kassel; Marc Navre; Lihong Shi; Robert J Skene; Tomoko Asakawa; Koji Takeuchi; Rongda Xu; David R Webb; Stephen L Gwaltney
Journal:  J Med Chem       Date:  2007-04-19       Impact factor: 7.446

9.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

Authors:  Mark Robson; Seock-Ah Im; Elżbieta Senkus; Binghe Xu; Susan M Domchek; Norikazu Masuda; Suzette Delaloge; Wei Li; Nadine Tung; Anne Armstrong; Wenting Wu; Carsten Goessl; Sarah Runswick; Pierfranco Conte
Journal:  N Engl J Med       Date:  2017-06-04       Impact factor: 91.245

10.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.

Authors:  Helen E Bryant; Niklas Schultz; Huw D Thomas; Kayan M Parker; Dan Flower; Elena Lopez; Suzanne Kyle; Mark Meuth; Nicola J Curtin; Thomas Helleday
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.